Study Affirms Safety Of COVID-19 mRNA Vaccine Targeting Omicron JN.1

HealthDay (8/6, Gotkine) reports a study found that “vaccination with the updated COVID-19 mRNA vaccine containing the severe acute respiratory syndrome coronavirus-2 Omicron JN.1 lineage was not associated with an increased risk for 29 adverse events.” The researchers observed “that during the 28-day risk period after receipt of a JN.1-containing mRNA vaccine, there were no significant increases in the rate of hospital contacts for any of 29 adverse events compared with reference period rates. The incidence rate ratios were 0.84, 0.92, and 1.12 for ischemic cardiac events, intracranial bleeding, and myocarditis, respectively.” The study was published in JAMA Network Open.